In addition, Wu et al performed a meta‐analysis of six regulatory submissions (37 525 participants) and 57 published trials (33 385 participants), which included seven different SGLT‐2 inhibitors.33 The authors found that the relative risk (RR) of cardiovascular death was 0.63 (0.51‐0.77, P < 0.0001) in favor of those treated with SGLT‐2 inhibitors and the RR of MACE was 0.84 (0.75‐0.95, P = 0.006).33 Non‐fatal stroke risk, with RR 1.3, was borderline increased (1.00‐1.68, P = 0.049). Here, SLC5A2 is linked to Stroke.